Cirrhosis future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}} {{AOEIC}} {{UJ}} | {{CMG}} {{AOEIC}} {{UJ}} | ||
==Overview== | ==Overview== | ||
Cirrhosis is a complication of Liver disease which result in irreversible scarring and loss of [[hepatocytes]]. Although there are many causes but [[Alcohol]] and [[Viral]] [[Hepatitis B]] and [[Hepatitis C|C]] are the main causes of cirrhosis. | Cirrhosis is a complication of Liver disease which result in irreversible [scar|scarring]] and loss of [[hepatocytes]]. Although there are many causes but [[Alcohol]] and [[Viral]] [[Hepatitis B]] and [[Hepatitis C|C]] are the main causes of cirrhosis. | ||
Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process. | Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process. | ||
Revision as of 13:42, 7 September 2012
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cirrhosis future or investigational therapies |
|
Risk calculators and risk factors for Cirrhosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Cirrhosis is a complication of Liver disease which result in irreversible [scar|scarring]] and loss of hepatocytes. Although there are many causes but Alcohol and Viral Hepatitis B and C are the main causes of cirrhosis.
Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process.
Future or Investigational Therapies
The following therapies are under trial:
- Obeticholic acid (OCA) for patients with primary biliary cirrhosis.[1]
- Boehringer Ingelheim’s investigational direct-acting antiviral compounds: BI 201335 (protease inhibitor) plus BI 207127 (polymerase inhibitor) for the treatment of Hepatitis C induced Cirrhosis.[2]
Reference
- ↑ Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.
- ↑ Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B; et al. (2011). "Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection". Gastroenterology. 141 (6): 2047–55, quiz e14. doi:10.1053/j.gastro.2011.08.051. PMID 21925126.